Day: July 7, 2026
Events

BioVentures Invites Community to Register for Innovation Day 2026

Turning promising discoveries into products, companies and technologies that improve lives takes more than great ideas. It takes collaboration between researchers, entrepreneurs, investors, industry partners and the organizations that help move innovation forward.  Those connections will be at the heart of BioVentures Innovation Day 2026, taking place August 19 from 8 a.m. to 6 p.m.on the 12th floor of the Jackson T. Stephens Spine & Neurosciences Institute at the University of Arkansas for Medical Sciences (UAMS) in Little Rock. Registration is now open for the one-day event, which will bring together innovators from across Arkansas and beyond to explore how research can become real-world impact.  Hosted by BioVentures, this year’s event is centered on the theme “From Discovery to Impact.” Throughout the day, attendees will hear from leaders in health care, life sciences and entrepreneurship while exploring topics including intellectual property, startup formation, funding strategies, medical device development, commercialization, regulatory pathways and industry partnerships.  Innovation Day is designed for researchers, clinicians, faculty, students, entrepreneurs, investors, industry professionals and community partners who are interested in advancing health care innovation and strengthening Arkansas’ life sciences ecosystem. In addition to educational sessions, attendees will have opportunities to network, connect with innovation support organizations and discover resources available to help translate research into new products and ventures.  Innovation Day is made possible through the support of organizations that share BioVentures’ commitment to advancing innovation and entrepreneurship across Arkansas, including Polsinelli, ARise, Wright, Lindsey & Jennings, Synapse Communications Consulting and Norton Rose Fulbright. Their partnership helps create opportunities for researchers, entrepreneurs and industry leaders to connect, collaborate and accelerate the commercialization of new health care technologies.  Whether attendees are taking their first steps toward commercialization or looking to expand an existing venture, Innovation Day offers an opportunity to learn from experienced leaders, build new partnerships and become part of Arkansas’ growing innovation network.  Registration for Innovation Day 2026 is now open. 

Read More »
July 7, 2026
Innovation

Licensing Spotlight: From UAMS Research to NuvOx’s NanO₂ Stroke Program

A technology developed at the University of Arkansas for Medical Sciences (UAMS) and licensed through BioVentures is continuing its path toward the clinic as NanO₂, an investigational oxygen therapeutic being developed by NuvOx Therapeutics for the treatment of acute ischemic stroke.  The underlying innovation was discovered by William C. Culp, M.D., Robert D. Skinner, Ph.D., and Evan C. Unger, M.D. and is based on dodecafluoropentane emulsion (DDFPe), a technology designed to enhance oxygen delivery to tissues affected by ischemia. During an ischemic stroke, blood flow to part of the brain is interrupted, depriving brain tissue of the oxygen needed to survive.  Early research at UAMS demonstrated the potential of DDFPe to support oxygen delivery to vulnerable brain tissue in preclinical models of ischemic stroke. These findings led to the development of intellectual property covering the use of DDFPe for stroke and ischemia, which was subsequently licensed to NuvOx Therapeutics through BioVentures.  Since licensing, the technology has continued to advance through both preclinical and clinical development. UAMS investigators evaluated intravenous DDFPe in an early randomized, controlled, dose-escalation clinical trial involving patients with acute ischemic stroke, generating data that supported continued clinical investigation.  Today, NuvOx is evaluating NanO₂ in NOVEL, a Phase IIb clinical trial in the UK with 150 patients with acute ischemic stroke caused by large vessel occlusion. The study is investigating NanO₂ in combination with standard reperfusion therapy and is designed to evaluate its ability to reduce brain infarct size by improving oxygen delivery to tissue at risk.  While NanO₂ remains an investigational therapy and has not yet been approved for general medical use, its progress illustrates how discoveries made within academic research institutions can evolve into promising therapeutic candidates through intellectual property protection, licensing, and industry partnership.  BioVentures is proud to support the commercialization of innovations that have the potential to improve patient care while translating groundbreaking university research into real-world impact. 

Read More »
July 7, 2026